Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Series A Convertible Preferred Stock	Series A-1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2020	$ (30,654)				$ 1,847		$ (32,501)
Balance, shares at Dec. 31, 2020				2,059,157
Temporary equity, Issuance of preferred stock upon modification and conversion of notes			$ 38,911
Temporary equity, Issuance of preferred stock upon modification and conversion of notes, shares			12,713,585
Issuance of preferrred stock upon modification and conversion of notes	1,735				1,735
Temporary equity, Acquisition of Oppilan and Zomagen			$ 18,526
Temporary equity, Acquisition of Oppilan and Zomagen, shares			6,052,911
Acquisition of Oppilan and Zomagen	2,820				2,820
Acquisition of Oppilan and Zomagen, shares				818,798
Temporary equity, Issuance of preferred stock and common stock, net of legal fees		$ 112,301
Temporary equity, Issuance of preferred stock and common stock, net of legal fees, shares		12,533,905
Issuance of preferred stock and common stock, net of legal fees					1,552		(1,552)
Issuance of preferred stock and common stock, net of legal fees, shares				507,133
Temporary equity, Conversion of tranche liability to Series A preferred stock and common stock		$ 3,978
Conversion of tranche liability to Series A preferred stock and common stock	3,058				3,058
Conversion of tranche liability to Series A preferred stock and common stock, shares				507,133
Issuance of common stock upon exercise of stock options	25				25
Issuance of common stock upon exercise of stock options, shares				12,540
Issuance of common stock upon vesting of restricted common stock, shares				51,212
Stock-based compensation expense	368				368
Foreign currency translation	(12)					$ (12)
Net loss	(53,204)						(53,204)
Temporary equity, Balance at Jun. 30, 2021		$ 116,279	$ 57,437
Temporary equity, Balance, shares at Jun. 30, 2021		12,533,905	18,766,496
Balance at Jun. 30, 2021	(75,864)				11,405	(12)	(87,257)
Balance, shares at Jun. 30, 2021				3,955,973
Temporary equity, Balance at Mar. 31, 2021		$ 55,301	$ 57,437
Temporary equity, Balance, shares at Mar. 31, 2021		6,283,401	18,766,496
Balance at Mar. 31, 2021	(63,662)				8,034	2	(71,698)
Balance, shares at Mar. 31, 2021				3,410,694
Temporary equity, Issuance of preferred stock and common stock, net of legal fees		$ 57,000
Temporary equity, Issuance of preferred stock and common stock, net of legal fees, shares		6,250,504
Temporary equity, Conversion of tranche liability to Series A preferred stock and common stock		$ 3,978
Conversion of tranche liability to Series A preferred stock and common stock	3,058				3,058
Conversion of tranche liability to Series A preferred stock and common stock, shares				507,133
Issuance of common stock upon exercise of stock options	25				25
Issuance of common stock upon exercise of stock options, shares				12,540
Issuance of common stock upon vesting of restricted common stock, shares				25,606
Stock-based compensation expense	288				288
Foreign currency translation	(14)					(14)
Net loss	(15,559)						(15,559)
Temporary equity, Balance at Jun. 30, 2021		$ 116,279	$ 57,437
Temporary equity, Balance, shares at Jun. 30, 2021		12,533,905	18,766,496
Balance at Jun. 30, 2021	(75,864)				11,405	(12)	(87,257)
Balance, shares at Jun. 30, 2021				3,955,973
Balance at Dec. 31, 2021	279,199			$ 5	397,051	(58)	(117,799)
Balance, shares at Dec. 31, 2021				50,408,830
Issuance of common stock upon exercise of stock options	$ 220				220
Issuance of common stock upon exercise of stock options, shares	417,332			417,332
Issuance of common stock upon vesting of restricted common stock, shares				63,830
Shares issued under employee stock purchase plan	$ 115				115
Shares issued under employee stock purchase plan, shares				9,074
Adjustment to offering expenses in the initial public offering	26				26
Stock-based compensation expense	7,575				7,575
Unrealized loss on marketable securities	(1,221)					(1,221)
Foreign currency translation	(12)					(12)
Net loss	(42,750)						(42,750)
Balance at Jun. 30, 2022	243,152			$ 5	404,987	(1,291)	(160,549)
Balance, shares at Jun. 30, 2022				50,899,066
Balance at Mar. 31, 2022	259,123			$ 5	400,607	(958)	(140,531)
Balance, shares at Mar. 31, 2022				50,729,820
Issuance of common stock upon exercise of stock options	134				134
Issuance of common stock upon exercise of stock options, shares				118,918
Issuance of common stock upon vesting of restricted common stock, shares				41,254
Shares issued under employee stock purchase plan	115				115
Shares issued under employee stock purchase plan, shares				9,074
Stock-based compensation expense	4,131				4,131
Unrealized loss on marketable securities	(279)					(279)
Foreign currency translation	(54)					(54)
Net loss	(20,018)						(20,018)
Balance at Jun. 30, 2022	$ 243,152			$ 5	$ 404,987	$ (1,291)	$ (160,549)
Balance, shares at Jun. 30, 2022				50,899,066